Open Orphan sets sights on €100m valuation

Open Orphan is targeting a valuation of €100 million in the next year after it completes the reverse takeover of drug services company Venn Life Sciences.

Open Orphan is currently in the middle of a fundraising round with the company seeking a modest amount of new cash, understood to be less than €10 million, from investors, according to market sources. The company and its advisers, IBI Corporate Finance, met with potential new investors ...